Articles

Using circulating tumor cell (CTC) count to guide the choice of first-line treatment—chemotherapy or endocrine therapy—improved overall survival (OS) compared with investigator’s choice of treatment for patients with metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to results from the STIC CTC trial, which were discussed at the 2022 San Antonio Breast Cancer Symposium (SABCS) by François-Clément Bidard, MD, PhD, Co-Coordinator, Breast Cancer Research, Institut Curie, Paris, France, and Professor, Medicine, Department of Medical Oncology, Institut Curie and Université de Versailles Saint-Quentin-en-Yvelines, France. Read More ›

In patients with hormone receptor (HR)-positive, HER2-low or -negative, locally advanced or metastatic breast cancer resistant to aromatase inhibitors, the addition of the investigational first-in-class AKT inhibitor capivasertib (AZD5363) to fulvestrant (Faslodex) led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with placebo plus fulvestrant. The PFS benefit observed with capivasertib was even greater in a subset of patients with an AKT pathway alteration. Read More ›

Recently, I had the privilege of representing the Association of Community Cancer Centers (ACCC) Oncology Workforce Subcommittee at the 39th National Oncology Conference—hosted in West Palm Beach, FL, from October 12 to 14, 2022—and speak about findings from the association’s 2022 Mini Z burnout survey, which was also conducted in 2019. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between December 9, 2022, and January 19, 2023. Read More ›

The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, is one of the 5 largest cancer centers in the United States, treating more than 70,000 patients each year. Read More ›

Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, including those with visceral crises, treated with the CDK4/6 inhibitor ribociclib (Kisqali) plus endocrine therapy had a significantly longer progression-free survival (PFS) and fewer adverse events (AEs) compared with those treated with combination chemotherapy, according to results from the phase 2 RIGHT Choice trial. Read More ›

Patients undergoing hematopoietic stem-cell transplantation (HSCT) do not derive any benefit from the restrictive diet frequently prescribed to prevent infections, according to the results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition. Read More ›

Engineers at Stanford University have created a small, autonomous device with a stretchable and flexible sensor that can be adhered to the skin to measure the changing size of tumors below. Read More ›

I am pleased to present the February issue of The Oncology Nurse-APN/PA (TON), a journal aimed at informing and empowering nurses, navigators, and advanced practice providers who work tirelessly to improve the lives of patients with cancer. Read More ›

The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA). Read More ›